Published in JAMA Surg on August 01, 2014
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures | NCT00042081
Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury. J Vasc Surg (2015) 0.82
Preservation solution impacts physiologic function and cellular viability of human saphenous vein graft. Surgery (2015) 0.79
An Optimized Preparation Technique for Saphenous Vein Graft. Am Surg (2015) 0.78
Searching for new meaning in PREVENT IV?: a project of ex-vivo vein graft engineering via transfection IV substudy. JAMA Surg (2014) 0.75
Traditional graft preparation decreases physiologic responses, diminishes viscoelasticity, and reduces cellular viability of the conduit: A porcine saphenous vein model. Vasc Med (2016) 0.75
Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis (1991) 1.75
Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA. Ann Thorac Surg (2003) 1.55
Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study). J Am Coll Cardiol (2012) 1.34
Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg (2013) 1.25
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J (2012) 1.22
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. Am Heart J (2005) 1.20
The natural history of endothelial structure and function in arterialized vein grafts. J Vasc Surg (1986) 1.11
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation (2012) 1.05
Localization of nitric oxide synthase in saphenous vein grafts harvested with a novel "no-touch" technique: potential role of nitric oxide contribution to improved early graft patency rates. J Vasc Surg (2002) 1.03
Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques. Ann Thorac Surg (2002) 1.01
Vein graft harvesting induces inflammation and impairs vessel reactivity. Ann Thorac Surg (2006) 0.99
Optimal preparation techniques for human saphenous vein grafts. Surgery (1980) 0.98
Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation (2002) 0.98
Even short-time storage in physiological saline solution impairs endothelial vascular function of saphenous vein grafts. Eur J Cardiothorac Surg (2011) 0.98
Endothelium-dependent relaxation in human saphenous vein grafts. Effects of preparation and clinicopathologic correlations. J Thorac Cardiovasc Surg (1990) 0.93
Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production. Ann Thorac Surg (2005) 0.93
University of Wisconsin solution and human saphenous vein graft preservation: preliminary anatomic report. Eur J Cardiothorac Surg (1993) 0.92
The integrity of experimental vein graft endothelium--implications on the etiology of early graft failure. Eur J Vasc Surg (1993) 0.91
Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy. Int J Clin Exp Med (2009) 0.90
The factors influencing early patency of coronary artery bypass vein grafts: correlation of angiographic and ultrastructural findings. J Thorac Cardiovasc Surg (1982) 0.89
In vivo human lower extremity saphenous vein bypass grafts manifest flow mediated vasodilation. J Vasc Surg (2009) 0.89
Functional and morphological evaluation of canine veins following preservation in different storage media. J Surg Res (1997) 0.88
Effect of peri-operative storage solution on the vascular reactivity of the human saphenous vein. Eur J Cardiothorac Surg (1993) 0.88
Pharmacologic relaxation of vein grafts is beneficial compared with pressure distention caused by upregulation of endothelial nitric oxide synthase and nitric oxide production. J Thorac Cardiovasc Surg (2006) 0.87
Influence of pressure on the endothelium of the saphenous vein coronary artery bypass graft. In Vivo (2007) 0.85
Storage of saphenous vein grafts prior to coronary artery bypass grafting: is autologous whole blood more effective than saline in preserving graft function? Interact Cardiovasc Thorac Surg (2012) 0.85
Ultrastructural investigations for reducing endothelial cell damage of vein grafts during CABG-operation and practical consequences. J Cardiovasc Surg (Torino) (1999) 0.82
Continuous graft perfusion: optimizing the quality of saphenous vein grafts. Heart Surg Forum (2002) 0.81
Preservation of endothelial vascular function of saphenous vein grafts after long-time storage with a recently developed potassium-chloride and N-acetylhistidine enriched storage solution. Thorac Cardiovasc Surg (2012) 0.81
Comparison of saphenous vein graft relaxation between Plasma-Lyte solution and normal saline solution. J Thorac Cardiovasc Surg (1994) 0.79
Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. Ann Thorac Surg (2013) 1.99
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol (2013) 1.51
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol (2015) 1.48
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2014) 0.85
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol (2013) 0.81
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol (2014) 0.80
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol (2015) 0.80
Appropriate Use Criteria for Coronary Revascularization and the Learning Health System: A Good Start. JAMA (2015) 0.75
Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA (2022) 0.75
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiol (2016) 0.75
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol (2017) 0.75